208 filings
Page 4 of 11
8-K
6x3d8cgnd9nz dv8g7
27 Sep 21
Aytu BioPharma Reports Fourth Quarter and Full-Year
4:20pm
8-K
hwi16a 9f2q
30 Aug 21
Departure of Directors or Certain Officers
5:15pm
8-K
1xrpmn
2 Jul 21
Entry into a Material Definitive Agreement
4:08pm
8-K
rcv p1i46vh7jj2oua
4 Jun 21
Entry into a Material Definitive Agreement
9:24pm
8-K
1slskkb i47fj9cbgc
21 May 21
Submission of Matters to a Vote of Security Holders
4:39pm
8-K/A
m8oig492ky5 g86b
21 May 21
Financial Statements and Exhibits
4:37pm
8-K
7bwpmm
20 May 21
Termination of a Material Definitive Agreement
12:00am
8-K
qeeo8g3tf9x lc6
17 May 21
Aytu BioPharma Reports Fiscal Third Quarter 2021 Financial Results and Recent Business Highlights
4:13pm
8-K
828pvj9w p7nt9u8roui
16 Apr 21
Aytu BioPharma Adds Late-Stage Pediatric Onset Rare Disease Asset to Development Pipeline from Rumpus Therapeutics
4:53pm
8-K
8wr01y4irlxd28pr6
5 Apr 21
Entry into a Material Definitive Agreement
4:07pm
8-K
2bric67
23 Mar 21
Other Events
4:06pm
8-K
igc391ats7vu1hp
22 Mar 21
Aytu BioScience Announces Close of Merger with Neos Therapeutics
6:19am
8-K
yma93p km2427komq4
11 Feb 21
Aytu BioScience Announces Record Fiscal Q2 2021 Net Revenue of $15.1 Million, an Increase of 377% Year-Over-Year
4:06pm
8-K
2mc05
25 Jan 21
Entry into a Material Definitive Agreement
4:04pm
8-K
or21px0u81801ip ngj
16 Dec 20
Other Events
9:03am
8-K
yvaj cp23s0f
15 Dec 20
Regulation FD Disclosure
2:27pm
8-K
16gbvpfgvt
14 Dec 20
Aytu BioScience Announces $10.0 Million Bought Deal Offering
7:18am
8-K
rgi 1zlbz
10 Dec 20
Regulation FD Disclosure
4:49pm
8-K
p2q9vj nr910b
10 Dec 20
Report of Independent Registered Public Accounting Firm
4:48pm
8-K
pa2g9 iwpvomsbsxjtz
10 Dec 20
Entry into a Material Definitive Agreement
4:33pm